Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy.

British journal of haematology - 1 Jul 1997

Oldenburg J, Quenzel E M, Harbrecht U, Fregin A, Kress W, Müller C R, Hertfelder H J, Schwaab R, Brackmann H H, Hanfland P

Abstract excerpt

Bleeding complications are the most common and unwanted side-effect of oral anticoagulant therapy. We report three patients in whom mutations in the factor IX (FIX) propeptide were found to cause severe bleeding during coumarin therapy. Strikingly, the bleeding occurred within the therapeutic ranges of the prothrombin time (PT) and international normalized ratio (INR). In all three patients coumarin therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticoagulants

Share to Factor IX

Share to Hemorrhage

Share to Mutation

Share to Peptide Fragments

Source

Identifiers

PMID: 9233593
DOI: 10.1046/j.1365-2141.1997.2213036.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy.PMID 9233593Read ↗

Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland.Semantic proximity Read ↗

Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy.Semantic proximity Read ↗

Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations.Semantic proximity Read ↗

Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10).Semantic proximity Read ↗

The Conundrum of "Warfarin Hypersensitivity": Prolonged Partial Thromboplastin Time From Factor IX Propeptide Mutation.Semantic proximity Read ↗

Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX.Semantic proximity Read ↗

Factor IX propeptide mutation and life threatening bleeding.Semantic proximity Read ↗

Factor IX Amagasaki: a new mutation in the catalytic domain resulting in the loss of both coagulant and esterase activities.Semantic proximity Read ↗

Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.Semantic proximity Read ↗

A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.Semantic proximity Read ↗

Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity.Semantic proximity Read ↗

FXIII deficiency due to base exchange Thr 449 (ACT) --> Ile (ATT) in exon 11 of the factor 13A gene. A cause of bleeding?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.